ATE552276T1 - Modifizierter anti-cd52-antikörper - Google Patents

Modifizierter anti-cd52-antikörper

Info

Publication number
ATE552276T1
ATE552276T1 AT04817412T AT04817412T ATE552276T1 AT E552276 T1 ATE552276 T1 AT E552276T1 AT 04817412 T AT04817412 T AT 04817412T AT 04817412 T AT04817412 T AT 04817412T AT E552276 T1 ATE552276 T1 AT E552276T1
Authority
AT
Austria
Prior art keywords
antibody
modified anti
antibodies
expected
potential
Prior art date
Application number
AT04817412T
Other languages
English (en)
Inventor
Francis Carr
Anita Hamilton
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE552276T1 publication Critical patent/ATE552276T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04817412T 2003-11-01 2004-10-29 Modifizierter anti-cd52-antikörper ATE552276T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51621003P 2003-11-01 2003-11-01
PCT/IB2004/003879 WO2005042581A2 (en) 2003-11-01 2004-10-29 Modified anti-cd52 antibody

Publications (1)

Publication Number Publication Date
ATE552276T1 true ATE552276T1 (de) 2012-04-15

Family

ID=34549504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04817412T ATE552276T1 (de) 2003-11-01 2004-10-29 Modifizierter anti-cd52-antikörper

Country Status (11)

Country Link
US (3) US7264806B2 (de)
EP (1) EP1694706B1 (de)
JP (1) JP4804357B2 (de)
CN (1) CN1898267B (de)
AT (1) ATE552276T1 (de)
BR (1) BRPI0416141B8 (de)
CA (1) CA2544365A1 (de)
DK (1) DK1694706T3 (de)
ES (1) ES2384105T3 (de)
PT (1) PT1694706E (de)
WO (1) WO2005042581A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2011202920C1 (en) * 2006-05-30 2012-11-15 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
EP2411050A4 (de) * 2009-03-25 2013-07-17 Vet Therapeutics Inc Antikörperregionen mit konstanter domäne und ihre verwendung
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
EP3345620B1 (de) 2009-05-13 2024-08-28 Genzyme Corporation Verfahren und zusammensetzungen zur lupus-behandlung
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP2542258A4 (de) * 2010-03-04 2013-08-21 Vet Therapeutics Inc Auf cd52 gerichtete monoklonale antikörper
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
CA3042620C (en) 2011-02-02 2025-12-30 Emory University Antagonism of the vip signaling pathway
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012138694A2 (en) 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
EP3559049B1 (de) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptidkonstrukte und anwendungen davon
JP6493692B2 (ja) * 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
EP2968450A4 (de) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modifizierte toxine
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
EP3218009B1 (de) 2014-10-14 2021-04-07 Polytherics Limited Verfahren zur konjugation eines peptids oder proteins mit einem reagenz mit abgangsgruppe mit einem peg-teil
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CN110709422B (zh) 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3720881A1 (de) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
US11471506B2 (en) 2018-04-23 2022-10-18 Emory University VIP antagonists and uses in treating cancer
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
US20260070986A1 (en) 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0945515A3 (de) 1989-11-06 2002-08-21 Cell Genesys, Inc. Herstellung von Proteinen mittels homologer Rekombination
EP0438310A1 (de) 1990-01-19 1991-07-24 Merck & Co. Inc. Verfahren zur Herstellung von rekombinanten Immunoglobulinen
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5846543A (en) 1995-10-24 1998-12-08 Hassler; Mark A. Bovine mastitis treatment
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
WO2002030460A2 (en) 2000-10-09 2002-04-18 Isis Innovation Ltd. Therapeutic antibodies
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
ATE469176T1 (de) * 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies

Also Published As

Publication number Publication date
CN1898267A (zh) 2007-01-17
WO2005042581A2 (en) 2005-05-12
US7264806B2 (en) 2007-09-04
US7910104B2 (en) 2011-03-22
US20050152898A1 (en) 2005-07-14
US20080075715A1 (en) 2008-03-27
ES2384105T3 (es) 2012-06-29
US20080248529A1 (en) 2008-10-09
JP2007534304A (ja) 2007-11-29
EP1694706A2 (de) 2006-08-30
DK1694706T3 (da) 2012-07-16
PT1694706E (pt) 2012-06-19
WO2005042581A3 (en) 2005-07-28
EP1694706B1 (de) 2012-04-04
BRPI0416141B1 (pt) 2019-01-15
BRPI0416141B8 (pt) 2021-05-25
CA2544365A1 (en) 2005-05-12
JP4804357B2 (ja) 2011-11-02
BRPI0416141A (pt) 2007-01-02
CN1898267B (zh) 2012-05-23
WO2005042581A8 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
DK1694706T3 (da) Modificeret anti-CD52-antistof
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
TW200745161A (en) Stable antibody formulation
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EA200800812A1 (ru) Композиции антитела против cd3
IL244803B (en) Human anti-beta antibodies and their use
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
ATE475672T1 (de) Anti-il-23-antikörper
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CO6270369A2 (es) Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas
CR10555A (es) Vacunas para malaria
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
MX2010001237A (es) Nuevos anticuerpos.
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3